| Acceptance rate | 46% |
|---|---|
| Time to first decision | 5 days* |
| Time to decision with review | 50 days* |
*approximate number of days
ACTA Pharmaceutica Sciencia
2003 , Vol 45 , Num 2
Triplicate Design Bioequivalence Studies